PRINCETON, N.J., Oct. 28, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that Christopher J. Schaber, PhD, President and Chief Executive Officer, Oreola Donini, PhD, Vice President of Preclinical Research and Development, and Stephen T. Sonis, DMD, DMSc, Clinical Professor of Oral Medicine at Harvard School of Dental Medicine, Senior Surgeon and Chief, Divisions of Oral Medicine at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, and Chief Scientific Officer of Biomodels, LLC, as well as Scientific Advisory Board Member and Lead Advisor for the Soligenix Phase 2 clinical study of SGX942 for the treatment of oral mucositis in head and neck cancer, will participate in an expert call and webcast, entitled: Oral Mucositis – Advancing the Next Generation of Therapies.
The expert call and webcast will be on November 1, 2013 at 2:00 PM EDT in a moderated format. The analyst moderator for the call will be Jason Kolbert, Managing Director of Biotechnology Research at the Maxim Group.
Dial-in for the conference call is 888-428-7458. To access the live audio webcast of the discussion, please log on through the link: http://www.infiniteconferencing.com/join with passcode 13274022. A replay of the webcast will be available one hour after the conclusion of the live event.
SGX942 is an innate defense regulator (IDR), a new class of short, synthetic peptides that has a novel mechanism of action in that it has simultaneous anti-inflammatory
|SOURCE Soligenix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved